



**Evidence Integration in Chemical Assessments:  
Challenges Faced in Developing and Communicating  
Human Health Effect Conclusions**

*The National  
Academies of* SCIENCES  
ENGINEERING  
MEDICINE

June 3-4, 2019

National Academy of Sciences (NAS) Building  
2101 Constitution Avenue, NW | Washington, DC 20418

SESSION I: Lessons Learned from Recent International Workshops on  
Evidence Integration in Risk Assessment

- Summary of recent workshops on evidence integration and systematic reviews
- Existing challenges on clarifying what is mechanism and what is biological plausibility
- Differences and commonalities in systematic reviews of public/clinical health & toxicology

## SESSION II: Best Practices in Evidence Integration

- IARC/Canadian approaches
- GRADE/OHAT concepts
- What are we rating our certainty in? What is the final message – differs between hazard and risk assessment
- Mechanisms required to understand exposure – outcome relation?
- Avoid research waste

SESSION III. Approaches for Using Mechanistic Data to Integrate Evidence from  
Animal and Human Studies: General Considerations

- PECO framework to rate indirectness
- Case studies and more on Bradford Hill
- Machine learning/AI – what are its applications?

## SESSION IV. Systematic Review-Enabled Evidence Integration: Case Studies

- Down to earth --- predictive modelling --- but how confident in your conclusions when extrapolated to people (animals)
- OHAT evidence integration on traffic related air pollution
- Data - risk of bias? – exclusion of evidence
- Value of Systematic Reviews


# Systematic review primer

Arch Toxicol (2017) 91:2551–2575  
DOI 10.1007/s00204-017-1980-3



REVIEW ARTICLE

## A primer on systematic reviews in toxicology


**Sebastian Hoffmann<sup>1,13</sup> · Rob B. M. de Vries<sup>2</sup> · Martin L. Stephens<sup>1</sup> · Nancy B. Beck<sup>3</sup> · Hubert A. A. M. Dirven<sup>4</sup> · John R. Fowle III<sup>5</sup> · Julie E. Goodman<sup>6</sup> · Thomas Hartung<sup>7</sup> · Ian Kimber<sup>8</sup> · Manoj M. Lalu<sup>9</sup> · Kristina Thayer<sup>10</sup> · Paul Whaley<sup>11</sup> · Daniele Wikoff<sup>12</sup> · Katya Tsaïoun<sup>1</sup>** 

Received: 13 April 2017 / Accepted: 4 May 2017 / Published online: 13 May 2017

© The Author(s) 2017. This article is an open access publication


# Thrombolysis in Myocardial Infarction

## Cumulative Systematic Reviews



# Negative Systematic Reviews

## Lidocaine in Myocardial infarction



Antman et al., JAMA, 1992; 268: 240-248

A

another example



## SESSION V. Practical Approaches to Expedited Evidence Integration

- Six step strategy to support decisions about exposures and test agents
- Elements of PRISMA and systematic reviews
- Short term or ultra short term risk assessments
- Clinical applications of evidence integration – how mechanistic evidence can inform evidence assessment

# Certainty in the evidence

## Interventions

- In vitro/In silico
- In vivo (animals)
- Human non-randomized studies/RCTs in animals
- RCTs in humans

## Exposures

- In vitro/In silico
- In vivo (animals)
- Human non-randomized studies/RCTs in animals
- RCTs and natural experiments in humans



# What's next?

- Systematic review methods upon you
  - friend or foe “new” in evidence integration
  - pillars of systematic reviews and evidence integration
  - cave: don't let traditional thinking and approaches determine the utility or application of systematic review methods (or make it fit) – scrutiny is good but need to leave some of the tradition behind
- Pragmatic but decision and human-focused methods required for evidence integration – we don't have many answers yet
- Need for more case studies with detailed problem formulation and integration of evidence that provides an answer to a PECO question - future workshops
- Keep on collaborating